RedHill Biopharma Ltd.

NasdaqCM:RDHL Stock Report

Market Cap: US$4.7m

RedHill Biopharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for RedHill Biopharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Sep 10

This Is Why RedHill Biopharma Ltd.'s (NASDAQ:RDHL) CEO Compensation Looks Appropriate

Key Insights RedHill Biopharma's Annual General Meeting to take place on 17th of September Total pay for CEO Dror...
Analysis Article • Jul 28

RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks

RedHill Biopharma Ltd.'s ( NASDAQ:RDHL ) price-to-sales (or "P/S") ratio of 0.1x might make it look like a strong buy...
Analysis Article • Nov 24

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Today is shaping up negative for RedHill Biopharma Ltd. ( NASDAQ:RDHL ) shareholders, with the covering analyst...
Seeking Alpha • Oct 18

RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency

RedHill Biopharma (NASDAQ:RDHL) received Nasdaq non compliance notification on October 12, 2022 regarding minimum bid price deficiency. The bid price for the company's ADSs had closed below the minimum $1.00/share for the last thirty consecutive business days.
Seeking Alpha • Aug 17

RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease

Israel-based RedHill Biopharma (NASDAQ:RDHL) announced Wednesday that the European Commission granted Orphan Drug Designation to RHB-204 as a treatment for nontuberculous mycobacteria (NTM) disease. The American depository shares of RDHL added ~5% in reaction. The decision follows a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). Pulmonary NTM lung disease is a chronic lung disease that affects an estimated 28,000 people in the EU. The advantages of European orphan drug designation include eligibility for ten years of post-launch market exclusivity. RDHL is in talks with partners to advance RHB-204 in multiple regions. A Phase 3 trial is currently underway in the U.S. to evaluate the candidate in adults with pulmonary NTM disease caused by its leading causative agent, Mycobacterium avium complex (MAC). With its recent financials, RedHill (RDHL) said that the waning COVID impact would likely speed up the program.

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RedHill Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:RDHL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20250-8-7-7N/A
6/30/202510-9-8-8N/A
3/31/20259-9-9-9N/A
12/31/2024N/A0-9-9N/A
9/30/20246-19-17-17N/A
6/30/20244-30-24-24N/A
3/31/20244-28-32-32N/A
12/31/2023N/A-18-17-17N/A
9/30/20231934-29-29N/A
6/30/20233612-26-26N/A
3/31/202352-1-32-32N/A
12/31/202262-72-29-29N/A
9/30/202271-92-42-42N/A
6/30/202275-78-55-55N/A
3/31/202278-95-57-57N/A
12/31/202186-98-65-65N/A
9/30/202185-98-63-63N/A
6/30/202184-95-54-54N/A
3/31/202184-82-103-50N/A
12/31/202064-76-102-49N/A
9/30/202044-64-104-50N/A
6/30/202025-55-102-48N/A
3/31/20206-50-45-44N/A
12/31/20196-42-41-41N/A
9/30/20196-38N/A-35N/A
6/30/20197-39N/A-35N/A
3/31/20198-39N/A-32N/A
12/31/20188-39N/A-34N/A
9/30/20189-42N/A-40N/A
6/30/20188-47N/A-43N/A
3/31/20186-47N/A-44N/A
12/31/20174-46N/A-45N/A
9/30/20172-43N/A-41N/A
6/30/20171-37N/A-38N/A
3/31/20170-32N/A-34N/A
12/31/20160-29N/A-28N/A
9/30/20160-28N/A-24N/A
6/30/20160-22N/A-20N/A
3/31/20160-22N/A-19N/A
12/31/20150-21N/A-18N/A
9/30/20150-20N/A-18N/A
6/30/20150-21N/A-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RDHL's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if RDHL's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if RDHL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RDHL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if RDHL's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RDHL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 15:01
End of Day Share Price 2026/05/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

RedHill Biopharma Ltd. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
null nullBTIG
Brandon FolkesCantor Fitzgerald & Co.